QUINTILES IMS HOLDINGS, INC. (NYSE:Q) Files An 8-K Entry into a Material Definitive AgreementItem 1.01
On September11, 2017, Quintiles IMS Incorporated (the “Issuer”), a wholly owned subsidiary of Quintiles IMS Holdings, Inc. (“QuintilesIMS”), entered into a purchase agreement with the representative of the purchasers named therein, relating to the issuance and sale of €420million in gross proceeds of senior notes due 2025 bearing interest at a rate of 2.875%. The consummation of the notes offering is subject to market and other conditions.
On September11, 2017, QuintilesIMS issued a press release announcing the pricing of the notes offering. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
|Item 1.01||Financial Statements and Exhibits.|
|99.1||Press Release dated September11, 2017.|
Quintiles IMS Holdings, Inc. ExhibitEX-99.1 2 d416345dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 News Release Contacts: Andrew Markwick,…To view the full exhibit click
About QUINTILES IMS HOLDINGS, INC. (NYSE:Q)
Quintiles IMS Holdings Inc, formerly Quintiles Transnational Holdings Inc., is a provider of biopharmaceutical development services and commercial outsourcing services. It is engaged in the development and commercialization of pharmaceutical therapies. Its segments include Product Development and Integrated Healthcare Services. Its Product Development segment is a contract research organization and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. The Integrated Healthcare Services segment includes commercial pharmaceutical sales and service organizations, and provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services for the healthcare sector, such as phase research, market access and consulting, health information analytics and technology consulting, and other healthcare solutions.